Clinical Trial Update: A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection [Phase 1]

View source ↗

Summary

The document reports results from a Phase 1 safety trial evaluating multiple doses of MEDI-507 to prevent acute renal allograft rejection. The study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Allograft Rejection

Drugs mentioned

• MEDI-507

Snippet

Sponsor: MedImmune LLC | Conditions: Kidney Diseases | Phase 1 | Status: COMPLETED